RIAS
STOK icon

Rachor Investment Advisory Services’s Stoke Therapeutics STOK Stock Holding History

Rachor Investment Advisory Services’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37
Closed -$1.21K – 398
2026
Q1 		$1.21K Sell
37
-3
-8% -$98 ﹤0.01% 305
2025
Q4 		$1.27K Buy
+40
New +$1.2K ﹤0.01% 281

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
GIM
Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
DWM
Dogwood Wealth Management Lenexa, Kansas $253M AUM 19.41% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Rachor Investment Advisory Services's STOK Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 37 shares — an estimated $1.21K sold.

Rachor Investment Advisory Services first reported a position in STOK in Q4 2025 and held it in 2 quarters. The position peaked at $1.27K in Q4 2025. 8 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 37 Stoke Therapeutics shares in Q2 2026, an estimated $1.21K.
  • Rachor Investment Advisory Services first reported a position in Stoke Therapeutics in Q4 2025 and held it in 2 quarters.
  • Rachor Investment Advisory Services's Stoke Therapeutics position peaked at $1.27K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.